Catherine C Smith Selected Research

gilteritinib

12/2022	Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib.
1/2022	Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib.
11/2020	Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations.
10/2020	Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor.
12/2019	The growing landscape of FLT3 inhibition in AML.
1/2019	Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Catherine C Smith Research Topics

Disease

17	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 12/2022 - 01/2012
5	Neoplasms (Cancer) 01/2022 - 04/2012
4	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 04/2013 - 01/2011
2	Leukemia 11/2021 - 01/2012
2	Malaria 09/2014 - 11/2011
1	Aneuploidy (Aneuploid) 12/2022
1	Pain (Aches) 12/2021
1	COVID-19 12/2021
1	Headache (Headaches) 12/2021
1	Hematologic Neoplasms (Hematological Malignancy) 01/2020
1	Postpartum Hemorrhage 08/2019
1	Acidosis 05/2019
1	Cardiac Arrhythmias (Arrythmia) 05/2019
1	Hypokalemia 05/2019
1	Ebola Hemorrhagic Fever 01/2018
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2018
1	Atrophy 06/2015
1	Mucositis 06/2015
1	Acute zonal occult outer retinopathy 06/2015
1	Fever (Fevers) 09/2014
1	Diarrhea 09/2014
1	Vomiting 09/2014
1	Peripheral Nervous System Diseases (PNS Diseases) 03/2014
1	Dyshidrotic Eczema (Pompholyx) 01/2007
1	Eczema 01/2007
1	HIV Infections (HIV Infection) 01/2007
1	Lymphoma (Lymphomas) 05/2006

Drug/Important Bio-Agent (IBA)

7	Tyrosine Kinase InhibitorsIBA 11/2020 - 01/2011
6	gilteritinibIBA 12/2022 - 01/2019
4	fms-Like Tyrosine Kinase 3IBA 01/2022 - 01/2012
4	Phosphotransferases (Kinase)IBA 01/2020 - 01/2012
2	Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA 12/2022 - 03/2016
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 12/2022 - 01/2020
2	midostaurinIBA 01/2022 - 12/2019
2	pexidartinibIBA 01/2021 - 01/2020
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 11/2020 - 06/2015
2	quizartinibIBA 01/2017 - 06/2015
1	ChromatinIBA 12/2022
1	Sorafenib (BAY 43-9006)FDA Link 01/2022
1	ChAdOx1 nCoV-19IBA 12/2021
1	VaccinesIBA 12/2021
1	Proteins (Proteins, Gene)FDA Link 11/2021
1	DNA (Deoxyribonucleic Acid)IBA 11/2021
1	Cyclin D3IBA 01/2021
1	Saline SolutionIBA 05/2019
1	ElectrolytesIBA 05/2019
1	MRX-2843IBA 03/2016
1	c-Mer Tyrosine KinaseIBA 03/2016
1	Retinaldehyde (Retinal)IBA 06/2015
1	Busulfan (Busulfex)FDA Link 06/2015
1	Etoposide (VP 16)FDA LinkGeneric 06/2015
1	Fluorescein (Funduscein)FDA LinkGeneric 06/2015
1	AntigensIBA 09/2014
1	Antimalarials (Antimalarial Agents)IBA 09/2014
1	ponatinibIBA 04/2013
1	Imatinib Mesylate (Gleevec)FDA Link 11/2011
1	Methyl MethanesulfonateIBA 05/2006
1	Dimethyl Sulfoxide (DMSO)FDA LinkGeneric 05/2006
1	SolventsIBA 05/2006
1	potassium bromateIBA 05/2006

Therapy/Procedure

12	Therapeutics 01/2022 - 01/2007
4	Drug Therapy (Chemotherapy) 12/2022 - 04/2013
2	Stem Cell Transplantation 01/2018 - 06/2015
1	Transplantation 01/2022
1	Cell Transplantation 01/2020
1	Blood Transfusion (Blood Transfusions) 08/2019
1	Uterine Myomectomy 05/2019
1	Hemodilution 05/2019
1	Hematopoietic Stem Cell Transplantation 06/2015
1	Chemoprevention 11/2011